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Abstract
Background: Modeling the relationship between age and mortality for breast cancer patients may
have important prognostic and therapeutic implications.
Methods: Data from 9 registries of the Surveillance, Epidemiology, and End Results Program
(SEER) of the United States were used. This study employed proportional hazards to model
mortality in women with T1-2 breast cancers. The residuals of the model were used to examine
the effect of age on mortality. This procedure was applied to node-negative (N0) and node-positive
(N+) patients. All causes mortality and breast cancer specific mortality were evaluated.
Results: The relationship between age and mortality is biphasic. For both N0 and N+ patients
among the T1-2 group, the analysis suggested two age components. One component is linear and
corresponds to a natural increase of mortality with each year of age. The other component is quasi-
quadratic and is centered around age 50. This component contributes to an increased risk of
mortality as age increases beyond 50. It suggests a hormonally related process: the farther from
menopause in either direction, the more prognosis is adversely influenced by the quasi-quadratic
component. There is a complex relationship between hormone receptor status and other
prognostic factors, like age.
Conclusion: The present analysis confirms the findings of many epidemiological and clinical trials
that the relationship between age and mortality is biphasic. Compared with older patients, young
women experience an abnormally high risk of death. Among elderly patients, the risk of death from
breast cancer does not decrease with increasing age. These facts are important in the discussion of
options for adjuvant treatment with breast cancer patients.
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Background
In many clinical situations, age is an important determi-
nant of treatment decision in breast cancer. For example,
after mastectomy, patients with T2 tumors and one to
three positive nodes are at high risk of isolated loco-
regional recurrences. Authors have advocated the routine
use of postmastectomy radiotherapy in those patients
who have T2 tumors and who are younger than 45 years
[1]. In another study about close margins at mastectomy,
the subgroup of patients aged 50 or younger with clinical
T1-2 tumors and 0–3 positive nodes who have close (5
mm or less) or positive margins were at high risk (28% at
8 years) for chest wall recurrence regardless of adjuvant
systemic therapy. Therefore, such patients should be con-
sidered for postmastectomy radiation [2]. Young women
aged less than 45 should be regarded as high-risk patients,
on the basis of age alone, and should be given adjuvant
cytotoxic treatment [3]. The latter study showed a non-lin-
ear relationship between age and relative risk of dying.
At the other end of the age spectrum, breast cancers in eld-
erly patients have been considered by some authors to
exhibit a less aggressive behavior than in younger patients
[4,5]. Other authors have argued that breast cancer does
not become more indolent as age increases [6].
There are still controversial issues about the relationship
between age and prognosis in breast cancer. Detailed
analysis would be useful in order to provide more insight
into this relationship. In the present study, we used pro-
portional hazards to model the survival of T1-2, node-
negative (N0) and node-positive (N+) breast cancer
patients. Outcomes which we considered included all-
cause mortality and cancer specific mortality from breast
cancer. The primary aim of the study is to present how age
relates with the risk of death. The secondary objective is to
search for a simple algebraic representation of this
relationship.
Methods
The Surveillance, Epidemiology, and End Results Program
(SEER) of the United States collected data about the inci-
dence of cancer and related matters from 11 population-
based registries [7]. The data extracted in this study was
from 9 registries: San Francisco-Oakland, Connecticut,
Metropolitan Detroit, Hawaii, Iowa, New Mexico, Seattle
(Puget Sound), Utah, and Metropolitan Atlanta. Selected
patients were women who were without previous history
of cancer and presented with non-inflammatory invasive
breast carcinoma, diagnosed and histologically confirmed
pT1-2 pM0 between 1988 and 1997, and for whom cura-
tive surgery and axillary lymph node dissections were per-
formed. In 1987, the American Joint Committee on
Cancer (AJCC) staging defined pT1 tumors as 2 cm or less
in greatest dimension, and pT2 tumor as more than 2 cm
but not more than 5 cm in greatest dimension. These def-
initions did not change until 1997. Some records were
rejected because of concerns about the quality of data:
non-hospital based data records, uncertain sequence of
treatment, unknown month of diagnosis and unknown
race. Records with missing histological grade and receptor
status were not excluded. Examination of statistical out-
liers excluded one case with 75 nodes involved. Events for
the study were death from all causes and death from
breast cancer. Follow-up cutoff date was December 31,
1999 as provided by the database.
In order to verify the linearity of the continuous variables,
the martingale residuals (differences between observed
and expected numbers of events) were used. The martin-
gale residuals were examined by a non-parametric
smoothing (fitting the scatter-plots of residuals) against
the quantitative covariates of interest. The smoothing
used a Poisson regression implementation of generalized
additive model (GAM) [8]. The GAM procedure provided
two outputs. One was the non-parametric smoothed
curves approximating the residuals. The other was a signif-
icance test of the non-linearity of the curves. For the cov-
ariates that significantly departed from linearity, an
iterative search was performed to identify parametric fam-
ilies of functions that approximated the curves. The crite-
ria used to end the search were: [a] simple parametric
expression, [b] the corresponding function introduced as
a transform in the Cox model satisfying the GAM linearity
test, and [c] without deteriorating the model fit as assessed
by the sum of squares of "deviance residuals" [8]. If the
transforms were valid, the graphical displays should be
linear shapes, and the non-linearity test results should be
non-significant. Finally, scaled Schoenfeld residuals were
used to verify that the relative hazards were constant over
time [9]. The hypothesis underlying this dual modeling
approach was as follows. If the algebraic functions are
valid, their use as plug-in transforms should appropriately
linearize the functional forms of the covariates of interest.
Other information about the implementation of these
procedures have been described earlier [10-12].
The analysis was applied first to node-negative cases
("training set") in order to find a simple expression of the
functional form which relates age to mortality. The func-
tional form obtained from node-negative cases was then
applied to node-positive cases ("validation set"). In addi-
tion to the validation with the same transformation which
was obtained for node-negative patients, a further itera-
tive search was performed in order to improve the fit for
node-positive patients.
This analysis was applied also to a European dataset, the
German Breast Cancer Study Group (GBSG-2), in which
the outcome studied was disease-free survival [14]. FromBMC Cancer 2005, 5:130 http://www.biomedcentral.com/1471-2407/5/130
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Table 1: Characteristics of the patients.
Characteristics of patients Total No. % of all cases Total N(0) % of all cases Total N(+) % of all cases
Patient number 83804 100.0% 58139 69.4% 25665 30.6%
SEER area:
East (Connecticut, Detroit, Atlanta) 31795 37.9% 21683 25.9% 10112 12.1%
Central (Iowa, New Mexico, Utah) 20459 24.4% 14202 16.9% 6257 7.5%
West (San Francisco-Oakland, Hawaii, Seattle) 31550 37.6% 22254 26.6% 9296 11.1%
Year of diagnosis:
1988–89 15390 18.4% 10424 12.4% 4966 5.9%
1990–91 16660 19.9% 11589 13.8% 5071 6.1%
1992–93 17042 20.3% 11894 14.2% 5148 6.1%
1994–95 17072 20.4% 11897 14.2% 5175 6.2%
1996–97 17640 21.0% 12335 14.7% 5305 6.3%
Age at diagnosis (years):
20–39 5869 7.0% 3396 4.1% 2473 3.0%
40–49 16231 19.4% 10262 12.2% 5969 7.1%
50–59 18051 21.5% 12362 14.8% 5689 6.8%
60–69 20703 24.7% 15110 18.0% 5593 6.7%
70–79 17161 20.5% 12802 15.3% 4359 5.2%
80+ 5789 6.9% 4207 5.0% 1582 1.9%
Race:
White and Other 78025 93.1% 54572 65.1% 23453 28.0%
Black 5779 6.9% 3567 4.3% 2212 2.6%
Marital status at diagnosis:
Single, widowed, other 33224 39.6% 23171 27.6% 10053 12.0%
Married 50580 60.4% 34968 41.7% 15612 18.6%
Topography:
Inner quadrant 12537 15.0% 9726 11.6% 2811 3.4%
Others 71267 85.0% 48413 57.8% 22854 27.3%
Histology:
Ductal 64370 76.8% 43924 52.4% 20446 24.4%
Others 19434 23.2% 14215 17.0% 5219 6.2%
Grade:
Poor/undifferentiated 25161 30.0% 15265 18.2% 9896 11.8%
Others 58643 70.0% 42874 51.2% 15769 18.8%
ER/PR status (+ includes unspecified):
ER+ and PR+ 63306 75.5% 44332 52.9% 18974 22.6%
ER+ and PR- 7001 8.4% 4852 5.8% 2149 2.6%
ER- and PR+ 2554 3.0% 1696 2.0% 858 1.0%
ER- and PR- 10943 13.1% 7259 8.7% 3684 4.4%
Tumor size (mm) (T stage):
< = 5 (T1a) 3349 4.0% 3069 3.7% 280 0.3%
> 5 and < = 10 (T1b) 16997 20.3% 14691 17.5% 2306 2.8%
> 10 and < = 20 (T1c) 36754 43.9% 26443 31.6% 10311 12.3%
> 20 and < = 50 (T2) 26704 31.9% 13936 16.6% 12768 15.2%
Number of nodes examined:
1–9 14225 17.0% 10525 12.6% 3700 4.4%
10–14 27004 32.2% 19210 22.9% 7794 9.3%
15–19 23102 27.6% 15820 18.9% 7282 8.7%
20+ 19473 23.2% 12584 15.0% 6889 8.2%BMC Cancer 2005, 5:130 http://www.biomedcentral.com/1471-2407/5/130
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a data analysis perspective, this GBSG-2 dataset is a very
different database of 686 patients containing some
extreme observations. One case had 51 involved nodes
(range for other patients 1–38), and another case had a
tumor size of 120 mm (range for other patients 3–100).
There were 299 events (either recurrence of disease or
death) in this German database.
The statistical analyses were performed with Splus
(Insightful Corporation, Seattle, WA, USA) statistical soft-
ware. Parametric fitting of curves used TableCurve 2D
(Systat Software Inc, Richmond, CA, USA).
Results
There are 83,804 T1-2 cases (58,139 N0 and 25,665 N+,
mean: 4 nodes involved, range: 1–48) available for analy-
sis from the SEER database. Table 1 shows the characteris-
tics of the patients. This table has been presented
elsewhere [13]. Except for 28 additional cases (because of
updated registration), there are no noticeable differences
in the distribution of the characteristics. Table 2 shows the
results of proportional hazards models in N0 and N+
groups, without using transforms for covariates. The sup-
plemental Table 2b (Additional file 1) shows results of the
check for Cox proportional hazards for all covariates.
Note that some P-values are very small because of the very
Number of nodes involved:
0 58139 69.4% 58139 69.4% 0 0.0%
1–3 16778 20.0% 0 0.0% 16778 20.0%
4+ 8887 10.6% 0 0.0% 8887 10.6%
Breast conserving surgery/Radiotherapy
no/no 46862 55.9% 31752 37.9% 15110 18.0%
no/yes 3972 4.7% 1024 1.2% 2948 3.5%
yes/no 4438 5.3% 2946 3.5% 1492 1.8%
yes/yes 28532 34.0% 22417 26.7% 6115 7.3%
ER = estrogen receptor, N(0) = node negative, N(+) = node positive, PR = progesterone receptor, SEER = Surveillance, Epidemiology, and End 
Results Program.
Table 2: Results of Cox proportional hazards models without transform. Hazard ratios (95% confidence intervals), values > 1 indicate 
increased risk of death.
Overall mortality Breast cancer specific mortality
N0 N+ N0 N+
SEER central area 1.00 (0.95–1.05) 0.93 (0.87–0.98) 1.03 (0.94–1.13) 0.92 (0.86–0.99)
SEER western area 0.92 (0.88–0.97) 0.87 (0.82–0.92) 0.82 (0.75–0.90) 0.86 (0.80–0.91)
Race black 1.38 (1.27–1.49) 1.42 (1.31–1.52) 1.37 (1.21–1.55) 1.44 (1.31–1.57)
Married 0.75 (0.72–0.78) 0.82 (0.78–0.86) 0.88 (0.81–0.95) 0.91 (0.86–0.97)
Inner quadrant 1.09 (1.04–1.15) 1.16 (1.08–1.24) 1.32 (1.21–1.44) 1.3 (1.19–1.41)
Ductal histology 1.14 (1.09–1.2) 1.11 (1.04–1.17) 1.44 (1.31–1.58) 1.12 (1.05–1.21)
ER negative 1.39 (1.28–1.5) 1.52 (1.41–1.64) 1.58 (1.4–1.78) 1.58 (1.44–1.73)
PR negative 1.11 (1.03–1.18) 1.27 (1.18–1.36) 1.36 (1.21–1.52) 1.39 (1.28–1.52)
Grade 3–4 1.23 (1.17–1.29) 1.34 (1.28–1.41) 1.6 (1.48–1.73) 1.48 (1.39–1.57)
BCS 1.12 (1.02–1.24) 0.96 (0.86–1.07) 1.01 (0.84–1.20) 0.98 (0.86–1.12)
Radiotherapy 1.12 (0.96–1.29) 0.89 (0.83–0.95) 1.31 (1.08–1.6) 0.91 (0.84–0.99)
BCSxRT 0.61 (0.51–0.73) 0.92 (0.8–1.06) 0.63 (0.48–0.82) 0.88 (0.74–1.04)
Year Diagnosis (continuous, year) 0.98 (0.97–0.99) 0.96 (0.95–0.97) 0.92 (0.91–0.94) 0.94 (0.93–0.95)
Age at Diagnosis (continuous, year) 1.05 (1.05–1.05) 1.02 (1.02–1.03) 1.00 (1.00–1.01) 1.00 (1.00–1.01)
Tumor size (continuous, mm) 1.03 (1.03–1.03) 1.02 (1.02–1.02) 1.05 (1.04–1.05) 1.02 (1.02–1.03)
Number positive nodes (continuous, n) (-) 1.07 (1.07–1.08) (-) 1.09 (1.08–1.09)
Number nodes examined (continuous, n) 0.99 (0.99–0.99) 0.98 (0.97–0.98) 0.99 (0.99–1.00) 0.97 (0.96–0.97)
BCS = breast conserving surgery, BCSxRT = breast conserving surgery and radiotherapy, ER = estrogen receptor, N0 = node negative, N+ = node 
positive, PR = progesterone receptor, SEER = Surveillance, Epidemiology, and End Results Program.
Table 1: Characteristics of the patients. (Continued)BMC Cancer 2005, 5:130 http://www.biomedcentral.com/1471-2407/5/130
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large size of the data. The rho-values (slope) indicate very
small departures from the assumption of proportional
hazards.
Figures 1 and 2 show graphically the effect of age on the
log hazard ratio for death from all causes, for N0 and N+
patients, respectively. Both curves have similar U-shapes.
The mortality is lowest for patients about 50 years of age
at diagnosis. The mortality increases the farther away from
50 years of age at diagnosis, for both younger and older
patients.
The shape of the smoothed curve for age suggests the use
of a quadratic function. A fractional polynomial analo-
gous to Sauerbrei and Royston [14], but with different
exponents, combining a linear term (age) and a quasi-
quadratic term |age-50|1.5, i.e. age+ |age-50|1.5, provides a
good fit and passes the test of linearity (Chi-square =
6.530, P = 0.089) in N0 patients (Table 3).
We note that the age transform derived from node-nega-
tive cases does not provide a perfect linearization in N+
patients (Table 3). A better linearization in N+ patients
was obtained by replacing the 1.5 exponent with 1.8,
though without improving global model fit (Table 3).
The proportional hazard check for age shows a deviation
from the assumption of constant hazard (Table 3). The
"rho" values are positive when considering overall mortal-
ity, i.e. an increasing risk of death with longer follow-up.
The values are negative when considering breast cancer
specific mortality, i.e. a decreasing risk of breast cancer
death with longer follow-up.
The age transforms suggest two components in the effect
of age. One component is linear (linear for the log hazard
ratio, i.e. exponential for the hazard ratio) and corre-
sponds to a natural increase in mortality with each year of
age. The other component is quasi-quadratic and is cen-
tered around age 50. It contributes to an increased risk of
mortality as age increases beyond 50. It suggests a hormo-
nally related process, not pre- versus post-menopausal,
but  perimenopausal  versus  non-perimenopausal
(premenopausal + postmenopausal). The further age at diag-
nosis is from the age at menopause, the more prognosis is
influenced by the quasi-quadratic component.
The results display a complex functional form of the effect
of age on mortality. The curves clearly highlight the bio-
logical anomaly that younger patients experience the
same relative mortality risk from all causes as do older
patients. Figures 1 and 2 show that a 30-year old patient
has a risk of death almost equal to a 60-year old patient.
The marked increase in mortality risk at older ages is
attributable to the increased risk of death from causes
other than breast cancer (co-morbidity). It should be
noted that breast cancer does not become less virulent in
older patients. An increase in the risk of death from breast
cancer associated with older age was observed both in N0
and in N+ patients (Figures 3 and 4).
Mortality for all causes as a function of age for N0 patients Figure 1
Mortality for all causes as a function of age for N0 patients. 
Dotted lines: twice-standard-error.
Mortality for all causes as a function of age for N+ patients Figure 2
Mortality for all causes as a function of age for N+ patients. 
Dotted lines: twice-standard-error.BMC Cancer 2005, 5:130 http://www.biomedcentral.com/1471-2407/5/130
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Table 3: Results of GAM and proportional hazards tests for SEER data
Overall mortality Node-negative Node-positive
no 
transform
transform 
age+|age-50|1.5
transform 
age+|age-50|1.8
no 
transform
transform 
age+|age-50|1.5
transform 
age+|age-50|1.8
GAM Chisq for Age (smaller value better) 582.4 6.53 52.4 439.2 18.4 1.83
GAM p-value for Age (larger better) <.0001 0.089 <.0001 <.0001 0.0003 0.557
Test PH for Age: rho (smaller absolute value better) 0.069 0.071 0.075 0.048 0.044 0.045
Test PH for Age: chisq (smaller value better) 53.6 46.3 48.2 21.1 15.8 16.0
Full PH model Rsquare (larger value better) 0.088 0.094 0.093 0.126 0.135 0.135
Full PH model Likelihood ratio test (larger value better) 5364 5745 5656 3443 3713 3709
Breast cancer specific mortality Node-negative Node-positive
no 
transform
transform 
age+|age-50|1.5
transform 
age+|age-50|1.8
no 
transform
transform 
age+|age-50|1.5
transform 
age+|age-50|1.8
GAM Chisq for Age (smaller value better) 52.7 11.1 8.10 63.7 9.20 4.92
GAM p-value for Age (larger better) <.0001 0.010 0.040 <.0001 0.027 0.179
Test PH for Age: rho (smaller absolute value better) -0.027 -0.038 -0.042 -0.007 -0.023 -0.027
Test PH for Age: chisq (smaller value better) 2.5 4.5 5.5 0.3 2.8 3.6
Full PH model Rsquare (larger value better) 0.03 0.03 0.031 0.1 0.1 0.1
Full PH model Likelihood ratio test (larger value better) 1779 1799 1803 2698 2715 2716
Chisq = chi-square value, GAM = generalized additive model, PH = proportional hazards. The additional file 3 "output4rev.doc" lists the output of 
the full PH models.
Breast cancer mortality as a function of age for N+ patients Figure 4
Breast cancer mortality as a function of age for N+ patients. 
Dotted lines: twice-standard-error.
Breast cancer mortality as a function of age for N0 patients Figure 3
Breast cancer mortality as a function of age for N0 patients. 
Dotted lines: twice-standard-error.BMC Cancer 2005, 5:130 http://www.biomedcentral.com/1471-2407/5/130
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The German Breast Cancer Study Group GBSG-2 dataset
[14] is a separate database of 686 patients. Using the GAM
procedure on the GBSG-2 data, age was significantly non-
linear (Chi2  = 31.744, 3 degrees of freedom, P <
0.000001). The age transforms improved the linearity for
the age variable, and also improved the proportional haz-
ards model (Table 4).
Discussion
In studies addressing the effect of age on breast cancer,
several authors have reported a biphasic mortality [15-
19]. This large study concurs with others in the literature.
As in any modeling, the validity and the utility of the
model may be questioned. Data from the GBSG-2 study
were considered for verification of the model. The GBSG-
2 study differs from the present SEER study in several
respects. This German study was a prospective controlled
clinical trial about the adjuvant treatment of node-posi-
tive breast cancer patients. Inclusion of patients was not
restricted by tumor size. Histopathological classification
and grading were performed centrally by one reference
pathologist. The GBSG-2 data have been extensively inves-
tigated for the effect of age on the prognosis of breast can-
cer [20]. The GBSG-2 data thus provide an indication of
the capability of our results to be extrapolated to a differ-
ent population. It is also complementary, since the SEER
has no data on recurrence and can provide no informa-
tion on disease-free survival.
Applying different methods to estimate the effect of age
on event-free survival of breast cancer (linear, categoriza-
tion based on cutpoints, classification and regression
trees, quadratic, fractional polynomial, cubic splines),
Hollaender found that all methods showed a decrease in
risk with increasing age up to 45–50 years [20]. A slight
increase in risk was observed for older patients in the
GBSG-2 data. Taking into account the wide confidence
intervals for ages older than 80 years, our Figure 4 for
node-positive breast cancer specific survival shows a good
concordance with the node-positive GBSG-2 event-free
survival.
Regarding the proportional hazards assumption, Hol-
laender noted that assuming a linear risk function, a small
correlation value rho of 0.147 was obtained [20]. Our
result for the GBSG-2 data shows the value of rho to be
0.131 (Table 4). The small difference is attributable to the
incorporation of different covariates to our proportional
hazards model (additional file 2 "outputgbsg2.doc"). For
the SEER data, the rho values are smaller (Table 3).
Our results are also in keeping with a closely related inves-
tigation of the SEER data in which a group of 4,616
patients 35 years old or younger was compared to a group
of 20,319 patients aged 50–55 years [21]. The authors
observed that younger breast cancer patients had poorer
survival explained in part by presentation with later stage
disease and more aggressive tumors, in terms of grade and
receptor status. But the known factors could not account
for the remaining unexplained difference in survival. In
contradiction, recently Rapiti et al have argued that age is
not an independent prognostic factor when accounting
for breast tumor characteristics and treatment [22]. How-
ever, this latter study included only 82 patients who were
35 years old or younger.
In order to try to understand the biphasic mortality, we
looked at hormonal status and treatments of the patients.
The age of 50 corresponds to the menopause. A large pro-
portion of younger women were estrogen receptor (ER)
negative (Figure 5). The proportion of ER-negative
patients decreases with increasing age without any
Table 4: Results of GAM and proportional hazards tests for GBSG-2 data
GBSG-2 data set no transform transform age+|age-50|1.5 transform age+|age-50|1.8
Hazard ratio for Age 1.001 1.004 1.002
p-value of Hazard ratio for Age 0.92 0.019 0.010
GAM Chisq for Age 31.74 9.29 8.70
GAM p-value for Age 0.0000006 0.0256 0.0336
Test PH for Age: rho 0.131 0.0459 0.0240
Test PH for Age: chisq 6.118 0.581 0.169
Full PH model Rsquare 0.135 0.142 0.143
Full PH model Likelihood ratio test 99.7 105 106
Chisq = chi-square value, GAM = generalized additive model, GBSG-2 = German Breast Cancer Study Group, PH = proportional hazards. The 
Additional file 2 "outputgbsg2.doc" lists the other covariates included in the PH models.BMC Cancer 2005, 5:130 http://www.biomedcentral.com/1471-2407/5/130
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inflection. On the other hand, the proportion of proges-
terone receptor (PR) negative patients increases at age 50
then slowly decreases again. The reporting of hormonal
receptor status is incomplete in SEER (~33–35% missing
data).
Data on systemic treatment were not available from the
SEER database, but the types of surgery and radiotherapy
were provided. Mastectomy was performed less frequently
on younger patients, but increased markedly among older
patients. Post-operative radiotherapy was given less fre-
quently at both ends of the age spectrum; somewhat less
frequently in the young and considerably less frequently
in the elderly patients (Figure 6). Researchers have
reported under-treatment of elderly patients and this fact
may account in part for the poor prognosis in the elderly
[23-25]. Whether hormonal status or type of treatment or
other factors may explain the biphasic mortality will need
to be researched.
There are several limitations in the present analysis. The
data are retrospective. Several orders of statistically signif-
icant interactions have not been incorporated in the
models. Receiving systemic treatment is a particularly
important prognostic factor in younger patients [3], but
data on systemic treatment were not available for analysis.
Despite the limitations and regardless of the modeling,
our major finding is that the relationship of age and
mortality is biphasic. Such a finding has been described
by many other authors [16,17,20,26]. It is important to
remember this biphasic relationship when analyzing the
effect of age on patients with breast cancer. Otherwise,
there is a substantial risk of misinterpreting results when
age is inappropriately categorized [26] or inappropriately
modeled. (Table 2 would suggest erroneously almost no
effect of age on mortality). Taking into account the full
shape of the relationship between age and breast cancer
specific mortality, we conclude that: 1) young women
experience a much higher risk of death than do older
patients; 2) among elderly patients, the risk of death from
breast cancer does not decrease with increasing age. These
are two facts that should be remembered by those when
discussing adjuvant treatment with breast cancer patients.
Conclusion
The present analysis confirms that the relationship
between age and mortality is biphasic. It is important that
clinical research takes this relationship into account.
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